Search

Your search keyword '"R. Gentilella"' showing total 71 results

Search Constraints

Start Over You searched for: Author "R. Gentilella" Remove constraint Author: "R. Gentilella"
71 results on '"R. Gentilella"'

Search Results

1. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

2. Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents

3. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

4. Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care

5. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c

6. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus

7. Once-weekly dulaglutide (DU) vs. insulin glargine in the control of fasting serum glucose and hypoglycaemia rate in the first 20 weeks in patients with type 2 diabetes mellitus on metformin and glimepiride

8. Author response for 'Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of Body Mass Index'

9. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index

10. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy

11. Personalized intensification of insulin therapy in type 2 diabetes – does a basal–bolus regimen suit all patients?

12. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

13. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

14. PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS

15. PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

16. PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

17. Consistency of treatment effect across the range of baseline HbA1c in patients with type 2 diabetes mellitus (T2DM) treated with once-weekly dulaglutide or comparators in AWARD-1, -5 and -6

18. Exenatide: a review from pharmacology to clinical practice

19. Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents

20. Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline HbA1c ≥7.5% after treatment with the once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA), dulaglutide, and active comparators in five clinical studies (AWARD 1 – 5)

21. Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

22. Evaluation of pre- and postprandial growth hormone (GH)-releasing hormone-induced GH response in subjects with persistent body weight normalisation after biliopancreatic diversion

23. Physiological role of the opioid-cholinergic interaction in growth hormone neuroregulation: Effect of sex and food intake

24. Préférences des patients selon leur âge pour les différentes caractéristiques des agonistes du récepteur du glucagon-like peptide-1 (GLP-1RA) dans le traitement du diabète au Royaume-Uni : un modèle de choix discret

25. Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data

26. Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study

27. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience

28. Profils d’auto-surveillance glycémique des patients diabétiques de type 2 (DT2) traités par dulaglutide (DU) hebdomadaire versus exénatide (EX) en prise bi-quotidienne (BID) et liraglutide (LIR) en prise quotidienne (OD) dans les études AWARD -1 et -6

29. Amélioration de l’HbA1c et du poids selon l’indice de masse corporelle (IMC) initial (<30, ≥30–<35 et≥35kg/m2) chez des patients diabétiques de type 2 (DT2) à 52 semaines de traitement par dulaglutide (DU) en administration hebdomadaire

30. P308 Impact de l’indice de masse corporelle (IMC ;< 30kg/m², ≥ 30 – < 35kg/m², et ≥ 35kg/m²) initial sur la réponse glycémique et les variations pondérales chez des patients diabétiques de type 2 (DT2) avec un taux initial d’HbA1c ≥ 7,5 % après traitement

31. GH and IGF-I as therapeutic agents for osteoporosis

32. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition

33. GH deficiency syndrome in elderly patients

34. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients

35. Opioid dysregulation after biliopancreatic diversion: effect of naloxone on preprandial and postprandial growth hormone (GH)-releasing hormone-induced GH release in surgically induced weight loss

36. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects

38. Effects of galanin on growth hormone and prolactin secretion in anorexia nervosa

39. Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone

41. Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.

42. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.

43. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.

44. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.

45. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.

46. Change in HbA 1c Across the Baseline HbA 1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.

47. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism.

48. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

49. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.

50. Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.

Catalog

Books, media, physical & digital resources